#United States #San Diego #Neurocrine Biosciences #Tardive Dyskinesia #Employment Impact

Understanding the Impact of Tardive Dyskinesia on Employment

In a recent announcement, Neurocrine Biosciences, Inc. revealed crucial findings from a survey that underscores the heavy toll of tardive dyskinesia (TD) on employment status and job responsibilities for those affected. The results come during Tardive Dyskinesia Awareness Week, a time when greater emphasis is placed on recognizing the condition's challenges and the critical need for improved awareness, diagnosis, and management.

Key Findings of the Survey

According to the survey, which involved 100 participants, including 70 adults diagnosed with TD and 30 caregivers, the results painted a stark picture of the challenges posed by this movement disorder. The respondents, on average around 47 years old, demonstrated the impact of uncontrolled involuntary movements typical of TD on their professional and personal lives. Here are some key findings from the survey:

• - Job Quitting: Approximately 20% of working adults with TD reported that they had left their jobs primarily due to symptoms associated with TD before receiving any form of treatment. This indicates a significant hurdle for those trying to maintain stable employment.
• - Work Interruptions: All participants indicated they missed an average of eight hours of work or school each week prior to initiating treatment for their condition, illustrating the disruptive nature of TD.

In a society that prioritizes productivity, these statistics reveal how conditions like tardive dyskinesia dramatically affect individuals' abilities to perform at work or in educational settings. Dr. Sanjay Keswani, Chief Medical Officer of Neurocrine Biosciences, stated, “These findings highlight how uncontrolled, involuntary movements associated with tardive dyskinesia can lead to reduced job responsibilities or even loss of employment.”

The Role of Caregivers

The survey also examined the burden on caregivers, who are often significantly impacted by their loved ones' symptoms. Among the 19 caregivers surveyed, interruptions to their daily lives were common, suggesting that the effects of TD reach far beyond the individual, influencing familial and social dynamics. This fateful connection underscores the importance of creating a comprehensive support system for both patients and their caregivers.

Importance of Early Recognition and Treatment

The survey results underscore the crucial necessity for early diagnosis and intervention. Current guidelines from the American Psychiatric Association recommend that patients showing moderate to severe symptoms of TD be treated with FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors. Despite these recommendations, it’s alarming that only about 10% of individuals with TD receive adequate treatment. This gap emphasizes the dire need for increased education and outreach to both healthcare providers and affected individuals.

Josie Cooper, Executive Director of the Movement Disorders Policy Coalition, commented, “Many people may not recognize that their uncontrolled movements are symptoms of tardive dyskinesia, which can affect many aspects of everyday life for adults.” Her words highlight the importance of greater awareness in order to encourage individuals to engage with healthcare providers about their symptoms.

Tardive Dyskinesia Awareness Week

Established in 2018, Tardive Dyskinesia Awareness Week aims to unite the mental health community in recognizing the comprehensive impacts of TD, as well as the need for continuous monitoring, early diagnosis, and effective treatments. Currently, it is estimated that TD affects at least 800,000 adults in the United States, yet a striking 60% of these individuals remain undiagnosed. The lack of recognition and understanding of the condition often leads to unmet healthcare needs for those living with TD.

Neurocrine Biosciences continues to advocate for education around TD, aiming to empower patients and their communities to initiate conversations concerning their health and treatment options. Resources like Neurocrine.com/TD-Awareness and TalkAboutTD.com provide vital information for both patients and healthcare providers about symptom recognition and management strategies.

Conclusion

As we observe Tardive Dyskinesia Awareness Week, the release of these survey results serves as a critical reminder of the real-world implications of TD. The findings reveal a pressing need for healthcare professionals to screen patients effectively, recognize the signs of TD, and provide timely treatment options that can alleviate the burdens associated with the disorder. By prioritizing awareness and education, we can work towards improving the lives of those affected by tardive dyskinesia and help them regain control over their futures.